Ranibizumab "Treat and Extend" in Diabetic Macular Edma (OPTIMAL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.
An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 18 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Visual impairment due to focal or diffuse macular edema with center involvement
Diabetes type 1 or 2, HbA1c < 12.0%
CRT = or > 250 μm
Active inflammation or infection
Iris neovascularization, active proliferative retinopathy or vitreomacular traction
Prior laser photocoagulation according to defined timelines
History of stroke, uncontrolled hypertension
Other protocol-defined inclusion/exclusion criteria may apply